BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...in Cytokinetics at $25 per share. Cytokinetics rose $3.86 (16%) to $27.88 Tuesday. Junshi taps Revitope’s...
...Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877) is paying $10 million for a 10% stake in Revitope Oncology Inc....
...Engaging Antibody Circuit (TEAC) platform. Junshi will have an exclusive, worldwide license to the compounds. Revitope...
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...was chairman and CEO of Celgene Corp. until its takeout by Bristol-Myers Squibb Co. (NYSE:BMY). Revitope Oncology Inc....
...evaluation at BMS. Elizabeth S. Eaton, Staff Writer Fred Hutchinson Cancer Research Center GlaxoSmithKline plc Provention Bio Inc. Antengene Corp. Ltd. Revitope Oncology Inc. Compugen...
BioCentury | Aug 2, 2018
Tools & Techniques

Model firsts

...of the thinking, versus just someone working in isolation developing the model.” Vikram Sinha, Merck Revitope Oncology Inc....
...it.” Last month, Revitope and Applied BioMath announced a collaboration to optimize the PK/PD of Revitope’s...
...Kenilworth, N.J. National Institutes of Health (NIH), Bethesda, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Revitope Oncology Inc....
BioCentury | Nov 4, 2016
Emerging Company Profile

Exploiting alpha-GAL

...will initially target high-EGFR-expressing cancers, but did not disclose specific indications or a development timeline. Revitope Oncology Inc....
...on the immune response against cytomegalovirus rather than alpha-GAL. Marron declined to compare the approaches. Revitope’s...
...Sandwich, U.K. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Kode Biotech Ltd., Auckland, New Zealand Revitope Oncology Inc....
BioCentury | Jun 20, 2016
Emerging Company Profile

Redirecting viral immunity

...three orders of magnitude stronger for the CMV-specific response versus a cancer-specific response," she said. Revitope's...
...the CMV immune response also increases in cancer patients, and increases even further following chemotherapy. Revitope's...
...LSE:HZD), Cambridge, U.K. Revitope Oncology Inc., San Francisco, Calif. References Hansen, S. "Sugar-coated bugs." BioCentury (2016) Sidebars Revitope Oncology Inc....
BioCentury | Feb 15, 2016
Financial News

Revitope completes venture financing

Revitope Oncology Inc. , San Francisco, Calif. Business: Cancer Date completed: 2016-02-08 Type: Venture financing Raised: $8.5 million WIR Staff cancer...
Items per page:
1 - 6 of 6
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...in Cytokinetics at $25 per share. Cytokinetics rose $3.86 (16%) to $27.88 Tuesday. Junshi taps Revitope’s...
...Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877) is paying $10 million for a 10% stake in Revitope Oncology Inc....
...Engaging Antibody Circuit (TEAC) platform. Junshi will have an exclusive, worldwide license to the compounds. Revitope...
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...was chairman and CEO of Celgene Corp. until its takeout by Bristol-Myers Squibb Co. (NYSE:BMY). Revitope Oncology Inc....
...evaluation at BMS. Elizabeth S. Eaton, Staff Writer Fred Hutchinson Cancer Research Center GlaxoSmithKline plc Provention Bio Inc. Antengene Corp. Ltd. Revitope Oncology Inc. Compugen...
BioCentury | Aug 2, 2018
Tools & Techniques

Model firsts

...of the thinking, versus just someone working in isolation developing the model.” Vikram Sinha, Merck Revitope Oncology Inc....
...it.” Last month, Revitope and Applied BioMath announced a collaboration to optimize the PK/PD of Revitope’s...
...Kenilworth, N.J. National Institutes of Health (NIH), Bethesda, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Revitope Oncology Inc....
BioCentury | Nov 4, 2016
Emerging Company Profile

Exploiting alpha-GAL

...will initially target high-EGFR-expressing cancers, but did not disclose specific indications or a development timeline. Revitope Oncology Inc....
...on the immune response against cytomegalovirus rather than alpha-GAL. Marron declined to compare the approaches. Revitope’s...
...Sandwich, U.K. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Kode Biotech Ltd., Auckland, New Zealand Revitope Oncology Inc....
BioCentury | Jun 20, 2016
Emerging Company Profile

Redirecting viral immunity

...three orders of magnitude stronger for the CMV-specific response versus a cancer-specific response," she said. Revitope's...
...the CMV immune response also increases in cancer patients, and increases even further following chemotherapy. Revitope's...
...LSE:HZD), Cambridge, U.K. Revitope Oncology Inc., San Francisco, Calif. References Hansen, S. "Sugar-coated bugs." BioCentury (2016) Sidebars Revitope Oncology Inc....
BioCentury | Feb 15, 2016
Financial News

Revitope completes venture financing

Revitope Oncology Inc. , San Francisco, Calif. Business: Cancer Date completed: 2016-02-08 Type: Venture financing Raised: $8.5 million WIR Staff cancer...
Items per page:
1 - 6 of 6